AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) gapped down before the market opened on Thursday . The stock had previously closed at $1.96, but opened at $1.91. AVEO Pharmaceuticals shares last traded at $1.85, with a volume of 2359401 shares changing hands.
A number of equities research analysts have recently commented on AVEO shares. BidaskClub upgraded shares of AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, September 11th. HC Wainwright set a $7.00 price target on shares of AVEO Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, October 23rd. Zacks Investment Research upgraded shares of AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a report on Monday. Finally, National Securities cut shares of AVEO Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Tuesday, November 6th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $5.31.
The firm has a market capitalization of $214.25 million, a PE ratio of -11.56 and a beta of 2.00.
A number of hedge funds have recently modified their holdings of the stock. NEA Management Company LLC boosted its holdings in AVEO Pharmaceuticals by 5.1% in the third quarter. NEA Management Company LLC now owns 18,698,038 shares of the biopharmaceutical company’s stock worth $61,891,000 after purchasing an additional 914,316 shares during the last quarter. BlackRock Inc. boosted its holdings in AVEO Pharmaceuticals by 2.1% in the third quarter. BlackRock Inc. now owns 7,120,894 shares of the biopharmaceutical company’s stock worth $23,570,000 after purchasing an additional 143,148 shares during the last quarter. Northern Trust Corp boosted its holdings in AVEO Pharmaceuticals by 396.0% in the second quarter. Northern Trust Corp now owns 1,098,075 shares of the biopharmaceutical company’s stock worth $2,482,000 after purchasing an additional 876,703 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in AVEO Pharmaceuticals by 14.9% in the third quarter. Bank of New York Mellon Corp now owns 331,010 shares of the biopharmaceutical company’s stock worth $1,096,000 after purchasing an additional 42,937 shares during the last quarter. Finally, Fosun International Ltd purchased a new stake in AVEO Pharmaceuticals in the third quarter worth approximately $1,090,000. Institutional investors own 50.92% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was first published by Week Herald and is the sole property of of Week Herald. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://weekherald.com/2018/11/16/aveo-pharmaceuticals-aveo-shares-gap-down-to-1-91.html.
AVEO Pharmaceuticals Company Profile (NASDAQ:AVEO)
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
Read More: Book Value Per Share in Stock Trading
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.